Literature DB >> 30737274

Elevated Expression of Macrophage Migration Inhibitory Factor Promotes Inflammatory Bone Resorption Induced in a Mouse Model of Periradicular Periodontitis.

Mohammed Howait1,2,3, Abdullah Albassam1,2,3, Chiaki Yamada4, Hajime Sasaki1,3,5, Laila Bahammam2, Mariane Maffei Azuma3,5, Luciano Tavares Angelo Cintra6, Abhay R Satoskar7, Satoru Yamada8, Robert White1, Toshihisa Kawai4, Alexandru Movila9,3,4.   

Abstract

Locally produced osteoclastogenic factor RANKL plays a critical role in the development of bone resorption in periradicular periodontitis. However, because RANKL is also required for healthy bone remodeling, it is plausible that a costimulatory molecule that upregulates RANKL production in inflammatory periradicular periodontitis may be involved in the pathogenic bone loss processes. We hypothesized that macrophage migration inhibitory factor (MIF) would play a role in upregulating the RANKL-mediated osteoclastogenesis in the periradicular lesion. In response to pulp exposure, the bone loss and level of MIF mRNA increased in the periradicular periodontitis, which peaked at 14 d, in conjunction with the upregulated expressions of mRNAs for RANKL, proinflammatory cytokines (TNF-α, IL-6, and IL-1β), chemokines (MCP-1 and SDF-1), and MIF's cognate receptors CXCR4 and CD74. Furthermore, expressions of those mRNAs were found significantly higher in wild-type mice compared with that of MIF-/- mice. In contrast, bacterial LPS elicited the production of MIF from ligament fibroblasts in vitro, which, in turn, enhanced their productions of RANKL and TNF-α. rMIF significantly upregulated the number of TRAP+ osteoclasts in vitro. Finally, periapical bone loss induced in wild-type mice were significantly diminished in MIF-/- mice. Altogether, the current study demonstrated that MIF appeared to function as a key costimulatory molecule to upregulate RANKL-mediated osteoclastogenesis, leading to the pathogenically augmented bone resorption in periradicular lesions. These data also suggest that the approach to neutralize MIF activity may lead to the development of a therapeutic regimen for the prevention of pathogenic bone loss in periradicular periodontitis.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30737274      PMCID: PMC6424624          DOI: 10.4049/jimmunol.1801161

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Structural and functional insights of RANKL-RANK interaction and signaling.

Authors:  Changzhen Liu; Thomas S Walter; Peng Huang; Shiqian Zhang; Xuekai Zhu; Ying Wu; Lucy R Wedderburn; Peifu Tang; Raymond J Owens; David I Stuart; Jingshan Ren; Bin Gao
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

Review 2.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

Review 3.  The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis.

Authors:  Richard Bucala; Idit Shachar
Journal:  Mini Rev Med Chem       Date:  2014       Impact factor: 3.862

4.  Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.

Authors:  Ran Gu; Leilani L Santos; Devi Ngo; HuaPeng Fan; Preetinder P Singh; Gunter Fingerle-Rowson; Richard Bucala; Jiake Xu; Julian M W Quinn; Eric F Morand
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

5.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment.

Authors:  Jürgen Bernhagen; Regina Krohn; Hongqi Lue; Julia L Gregory; Alma Zernecke; Rory R Koenen; Manfred Dewor; Ivan Georgiev; Andreas Schober; Lin Leng; Teake Kooistra; Günter Fingerle-Rowson; Pietro Ghezzi; Robert Kleemann; Shaun R McColl; Richard Bucala; Michael J Hickey; Christian Weber
Journal:  Nat Med       Date:  2007-04-15       Impact factor: 53.440

6.  RANKL in human periapical granuloma: possible involvement in periapical bone destruction.

Authors:  R Vernal; A Dezerega; N Dutzan; A Chaparro; R León; S Chandía; A Silva; J Gamonal
Journal:  Oral Dis       Date:  2006-05       Impact factor: 3.511

7.  Inflammatory infiltrate of chronic periradicular lesions: an immunohistochemical study.

Authors:  S Liapatas; M Nakou; D Rontogianni
Journal:  Int Endod J       Date:  2003-07       Impact factor: 5.264

8.  Immunolocalization of bone-resorptive cytokines in rat pulp and periapical lesions following surgical pulp exposure.

Authors:  N Tani-Ishii; C Y Wang; P Stashenko
Journal:  Oral Microbiol Immunol       Date:  1995-08

Review 9.  Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss.

Authors:  Tania N Crotti; Anak A S S K Dharmapatni; Ekram Alias; David R Haynes
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

10.  The Association of Higher Plasma Macrophage Migration Inhibitory Factor Levels with Lower Bone Mineral Density and Higher Bone Turnover Rate in Postmenopausal Women.

Authors:  Hyeonmok Kim; Seong Hee Ahn; Chaeho Shin; Seung Hun Lee; Beom Jun Kim; Jung Min Koh
Journal:  Endocrinol Metab (Seoul)       Date:  2016-07-26
View more
  2 in total

1.  Immunomodulation Mediated by Azithromycin in Experimental Periapical Inflammation.

Authors:  Ana Cristina Andrada; Mariane Maffei Azuma; Hisako Furusho; Kimito Hirai; Shuang Xu; Robert R White; Hajime Sasaki
Journal:  J Endod       Date:  2020-08-05       Impact factor: 4.171

2.  Effects of statins on cytokines levels in gingival crevicular fluid and saliva and on clinical periodontal parameters of middle-aged and elderly patients with type 2 diabetes mellitus.

Authors:  Huiyuan Zhang; Yameng Zhang; Xiaochun Chen; Juhong Li; Ziyang Zhang; Haiyang Yu
Journal:  PLoS One       Date:  2021-01-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.